ADC Therapeutics ends development of ADCT-602 and unveils latest Zynlonta data

ADC Therapeutics has culled its objective plus ADCT-602 portion announcing much information connected its flagship cause Zynlonta (loncastuximab tesirine-lpyl).

Following the 2 announcements, the company’s stock, listed connected the New York Stock Exchange (NYSE), closed 37.12% higher, from a $1.32 adjacent connected 13 May to a $1.81 adjacent connected 14 May.

The Swiss biotech has halted improvement of ADCT-602, which was being assessed successful a Phase I/II proceedings (NCT03698552) successful patients with relapsed oregon refractory B-cell acute lymphoblastic leukaemia (ALL).

The proceedings was sponsored by the M D Anderson Cancer Center and aimed to enrol 57 patients with the anticipation of evaluating the information and determining the recommended dose portion besides gaining accusation connected the therapy’s efficacy by implicit effect (CR) with an incomplete marrow betterment rate.

The lone different objective plus successful the company’s pipeline present is ADCT-701, which is presently being evaluated successful a Phase I, first-in-human survey (NCT06041516) successful patients with neuroendocrine tumours and carcinomas. The superior nonsubjective of the proceedings is to find the maximum tolerated dose.

The institution besides has a assortment of assets successful the preclinical signifier of development.

In a abstracted announcement connected 14 May, ADC Therapeutics announced further affirmative information for Zynlonta, a CD19-directed antibody-drug conjugate (ADC), successful operation with Roche’s Columvi (glofitamab) from the Phase Ib LOTIS-7 proceedings (NCT04970901).

The caller information shows the operation had a 95.5% wide effect complaint (ORR) and 90.9% CR complaint successful 22 patients with relapsed oregon refractory diffuse ample B-cell lymphoma (DLBCL). The median duration of effect (DoR) has not yet been reached.

ADC Therapeutics volition beryllium presenting the information astatine some the European Hematology Association 2025 Congress (EHA2025) successful Milan, Italy, successful June and the 18th International Conference connected Malignant Lymphoma 2025 (ICML) successful Lugano, Switzerland, successful July.

Zynlonta was approved done the US Food and Drug Administration’s (FDA) accelerated support pathway successful April 2021 for the attraction of DLBCL based connected information from the Phase II LOTIS-2 proceedings (NCT03589469).

In December 2024, the institution completed the Phase III LOTIS-5 survey (NCT04384484), which is required arsenic the confirmatory survey to summation afloat support done a supplemental biologics licence exertion (BLA) with the FDA. The institution volition besides contiguous updated LOTIS-5 information run-in information evaluating Zynlonta positive rituximab astatine EHA2025.

Zynlonta besides received a conditional selling authorisation valid throughout the EU connected 20 December 2022.